Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer—Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy

AKT as a Therapeutic Target for Cancer

(2019) Mengqiu Song et al.   CANCER RESEARCH

Genomic characterization of metastatic breast cancers

(2019) François Bertucci et al.   NATURE

Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

(2019) Fabrice André et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular basis for class side effects associated with PI3K/AKT/mTOR pathway inhibitors

(2019) Ying Zhang et al.   Expert Opinion on Drug Metabolism & Toxicology

Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy

(2018) Sarika Jain et al.   BREAST CANCER RESEARCH AND TREATMENT

Oncogenic Signaling Pathways in The Cancer Genome Atlas

(2018) Francisco Sanchez-Vega et al.   CELL

The Strategy of PIKing a Target: What Is AKTually Most Effective?

(2018) Carlotta Costa et al.   CLINICAL CANCER RESEARCH

Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

(2018) Dejan Juric et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

(2018) Alexander Drilon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Impairment of Akt activity by CYP2E1 mediated oxidative stress is involved in chronic ethanol-induced fatty liver

(2018) Tao Zeng et al.   Redox Biology

The Akt pathway in oncology therapy and beyond (Review)

(2018) George Nitulescu et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

AKT Inhibition in Solid Tumors With AKT1 Mutations

(2017) David M. Hyman et al.   JOURNAL OF CLINICAL ONCOLOGY

Breast cancer

(2017) Nadia Harbeck et al.   LANCET

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) José Baselga et al.   LANCET ONCOLOGY

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas

(2016) A. Patnaik et al.   ANNALS OF ONCOLOGY

AKT1 E17K mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection

(2016) Marion Rudolph et al.   BMC CANCER

A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER + /HER2 − Metastatic Breast Cancer

(2016) Ingrid A. Mayer et al.   CLINICAL CANCER RESEARCH

BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models

(2016) Oliver Politz et al.   INTERNATIONAL JOURNAL OF CANCER

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005)

(2015) Ramesh K. Ramanathan et al.   CANCER

Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079)

(2015) B. B. Y. Ma et al.   INVESTIGATIONAL NEW DRUGS

Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors

(2015) B. R. Davies et al.   MOLECULAR CANCER THERAPEUTICS

Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer

(2015) Daniel H. Ahn et al.   Scientific Reports

Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers

(2014) T. A. Yap et al.   CLINICAL CANCER RESEARCH

Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2

(2013) J. Thaddeus Beck et al.   BREAST CANCER RESEARCH AND TREATMENT

Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study

(2013) Nicolai Maass et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Phase II trial of temsirolimus in patients with metastatic breast cancer

(2012) Gini F. Fleming et al.   BREAST CANCER RESEARCH AND TREATMENT

Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer

(2012) T. Sangai et al.   CLINICAL CANCER RESEARCH

Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

(2012) B. R. Davies et al.   MOLECULAR CANCER THERAPEUTICS

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

(2011) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

(2011) Johanna C. Bendell et al.   JOURNAL OF CLINICAL ONCOLOGY

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

(2010) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163

(2009) Susan L. Ellard et al.   JOURNAL OF CLINICAL ONCOLOGY

AKT1 E17K in human solid tumours

(2008) F E Bleeker et al.   ONCOGENE